Replies to post #320277 on Innovation Pharmaceuticals Inc (IPIX)

[Minnesinger]

The only hint I read...

is that if Brilacidin enters P2 and performs well enough to proceed to P3, there will be no delay between trials - at least none due to the need to manufacture more IV solution. Strikes me as prudent and sensible.

“Lastly, the manufacturing of Brilacidin intravenous (IV) drug product is expected to produce an amount in excess of what is estimated to be required for the Company’s planned Phase 2 clinical trial, allowing for extra IV drug product to support potential additional COVID-19 clinical testing.”

Hint hint friends.